आकुम्स ड्रग्स आणि फार्मास्युटिकल्स शेअर प्राईस

Q4FY26 आणि पूर्ण वर्षाची कामगिरी आणि दृष्टीकोन यावर अकुम्स ड्रग्स अँड फार्मास्युटिकल्स मॅनेजमेंट आणि विश्लेषकांसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 3 आठवडे 2 दिवसांपूर्वी

Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 11,578.68 million, representing a YoY growth of 9.69% compared to Rs 10,555.47 million in Q4FY25 and a marginal QoQ decline of 0.15% from Rs 11,595.87 million in Q3FY26. Total Income for Q4FY26 was Rs 11,931.69 million, an increase of 11.19% YoY from Rs 10,730.92 million and a minor QoQ decrease of 0.06% from Rs 11,939.15 million. Profit before Tax for the quarter was Rs 1,212.16 million, registering a growth of 61.33% YoY compared to Rs 751.36 million and an increase of 21.74% QoQ from Rs 995.66 million. Net Profit for Q4FY26 reached Rs 813.42 million, a decrease of 45.63% YoY from Rs 1,496.06 million but a QoQ increase of 20.19% compared to Rs 676.74 million in Q3FY26. For the full year ended March 31, 2026, Revenue from Operations was Rs 43,590.17 million, reflecting a growth of 5.85% YoY compared to Rs 41,181.58 million in FY25. Annual Net Profit for FY26 stood at Rs 2,563.97 million, representing a YoY decline of 25.42% compared to Rs 3,437.77 million in FY25. Earnings Per Share (EPS) for Q4FY26 was Rs 5.53, while the annual EPS for FY26 was Rs 16.67, compared to Rs 22.60 in FY25. The Board has recommended a final dividend of Rs 1.00 per equity share and a special dividend of Rs 2.00 per equity share for FY26. Standalone Financial Highlights: Revenue from Operations for Q4FY26 was Rs 3,383.72 million, showing a YoY growth of 2.93% from Rs 3,287.53 million in Q4FY25 and a QoQ decline of 8.20% from Rs 3,686.06 million in Q3FY26. Total Income for the quarter stood at Rs 3,661.01 million, up 1.47% YoY from Rs 3,608.03 million and down 8.06% QoQ from Rs 3,982.10 million. Profit before Tax for Q4FY26 reached Rs 217.91 million, registering a YoY decrease of 41.19% compared to Rs 370.55 million and a QoQ decrease of 39.25% from Rs 358.67 million. Net Profit for the quarter was Rs 151.97 million, a decline of 44.92% YoY as against Rs 275.89 million and a decline of 45.94% QoQ from Rs 281.14 million. For FY26, Standalone Revenue from Operations was Rs 13,487.36 million, up from Rs 13,117.84 million in FY25. Annual Standalone Net Profit for FY26 stood at Rs 1,116.40 million, showing a decline of 30.66% compared to Rs 1,609.98 million in FY25. Business Highlights: Segment Performance: CDMO (Contract Development and Manufacturing operations): Revenue reached Rs 34,851.99 million compared to Rs 32,078.76 million in FY25. Segment results stood at Rs 3,290.31 million. API (Active Pharmaceutical Ingredient): Revenue was Rs 1,844.35 million compared to Rs 2,192.96 million in FY25. The segment recorded a loss of Rs 576.55 million. Domestic Branded Formulations: Revenue stood at Rs 4,463.04 million compared to Rs 4,335.88 million in FY25. Segment results reached Rs 872.38 million. International Branded Formulations: Revenue was Rs 1,434.62 million compared to Rs 1,426.13 million in FY25. Segment results stood at Rs 342.31 million. Trade Generics: Revenue reached Rs 996.17 million as against Rs 1,147.85 million in FY25. The segment recorded a loss of Rs 113.93 million. Initial Public Offer (IPO): The Company completed its IPO and listed its shares on August 6, 2024. The issue comprised a fresh issue of Rs 6,800.00 million and an offer for sale of Rs 11,767.37 million. Net proceeds to the Company, after IPO expenses and reallocations, were utilized for debt repayment, working capital, and inorganic growth. Exceptional Items: Consolidated exceptional items for FY26 amounted to Rs 200.24 million, comprising the impact of changes in the labour code (Rs 162.12 million) and retrospective wage revision/VDA arrears (Rs 38.12 million). Subsidiary Acquisitions: During the year, the Company added Akums Healthcare Zambia Private Limited (effective 13 October 2025) and Akums Healthcare Malta Private Limited (effective 20 October 2025) as subsidiaries. Corporate Changes: The Board approved the appointment of Mr. V Jagannathan as President – HR, following the cessation of Mr. Arvind Srivastava from the same role effective May 14, 2026. Result PDF

• ट्रेंडलाईन
• 3 आठवडे 6 दिवसांपूर्वी

नॅशनल स्टॉक एक्सचेंज (एनएसई) वर इंट्राडे ट्रेडमध्ये अकुम्स ड्रग्स आणि फार्मास्युटिकल्स शेअरची किंमत 6 टक्के वाढून 505.90 झाली

• बिझनेस स्टँडर्ड
• 3 महिने 3 आठवड्यांपूर्वी